T1	intervention 7 16	docetaxel
T2	control 24 27	CMF
T6	outcome 929 960	Grades 3-4 hematological events
T7	cv-bin-abs 978 980	37
T8	cv-bin-percent 982 987	69.8%
T9	iv-bin-abs 993 994	4
T10	iv-bin-percent 996 1000	8.3%
T11	outcome 1023 1060	grades 3-4 non-hematological toxicity
T12	cv-bin-abs 1064 1066	12
T13	cv-bin-percent 1068 1073	22.6%
T14	iv-bin-abs 1079 1081	15
T15	iv-bin-percent 1083 1088	31.2%
T16	outcome 794 828	grades 3-4 toxic event of any type
T17	cv-bin-abs 845 847	40
T18	cv-bin-percent 849 854	75.5%
T19	iv-bin-abs 860 862	19
T20	iv-bin-percent 864 869	39.6%
T21	total-participants 675 678	101
T23	control-participants 740 742	53
T24	intervention-participants 767 769	48
T22	age 709 711	70
T25	eligibility 251 337	early breast cancer patients, 65-79 years old, with average to high risk of recurrence
T26	outcome 1499 1507	toxicity
T5	outcome 1169 1175	anemia
T27	outcome 1177 1188	neutropenia
T28	outcome 1190 1206	thrombocytopenia
T29	outcome 1211 1230	febrile neutropenia
T3	outcome 1254 1266	Constipation
T30	outcome 1268 1277	mucositis
T31	outcome 1279 1285	nausea
T32	outcome 1290 1298	vomiting
T4	outcome 1326 1335	diarrhoea
T33	outcome 1337 1351	abdominal pain
T34	outcome 1353 1362	dysgeusia
T35	outcome 1364 1374	neuropathy
T36	outcome 1379 1393	liver toxicity
